ValuEngine downgraded shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a research note released on Thursday morning, ValuEngine reports.
Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Lantheus from a buy rating to a hold rating in a research report on Wednesday, April 24th. BidaskClub lowered shares of Lantheus from a strong-buy rating to a buy rating in a research report on Tuesday, June 11th.
LNTH remained flat at $$22.49 during trading on Thursday. 428,304 shares of the company’s stock were exchanged, compared to its average volume of 438,680. The company has a debt-to-equity ratio of 2.05, a current ratio of 2.62 and a quick ratio of 2.01. Lantheus has a 1 year low of $12.59 and a 1 year high of $29.80. The stock has a 50 day moving average of $26.98. The stock has a market cap of $873.06 million, a PE ratio of 23.93, a P/E/G ratio of 1.79 and a beta of 1.48.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.27. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. The firm had revenue of $85.70 million for the quarter, compared to analyst estimates of $88.72 million. During the same quarter in the previous year, the firm posted $0.25 earnings per share. The business’s revenue was up .1% on a year-over-year basis. Research analysts predict that Lantheus will post 1.06 earnings per share for the current fiscal year.
In other news, COO John J. Bolla sold 1,747 shares of the business’s stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $27.56, for a total value of $48,147.32. Following the sale, the chief operating officer now owns 37,155 shares of the company’s stock, valued at $1,023,991.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Michael P. Duffy sold 8,819 shares of the business’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $28.14, for a total transaction of $248,166.66. Following the transaction, the senior vice president now owns 144,494 shares in the company, valued at $4,066,061.16. The disclosure for this sale can be found here. In the last three months, insiders sold 146,187 shares of company stock worth $3,853,913. 2.60% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Hillsdale Investment Management Inc. increased its holdings in Lantheus by 28.2% during the second quarter. Hillsdale Investment Management Inc. now owns 132,800 shares of the medical equipment provider’s stock worth $3,758,000 after buying an additional 29,200 shares during the last quarter. Swiss National Bank increased its holdings in Lantheus by 2.3% during the second quarter. Swiss National Bank now owns 71,700 shares of the medical equipment provider’s stock worth $2,029,000 after buying an additional 1,600 shares during the last quarter. Envestnet Asset Management Inc. acquired a new position in Lantheus during the second quarter worth $578,000. TD Asset Management Inc. increased its holdings in Lantheus by 1.4% during the second quarter. TD Asset Management Inc. now owns 63,009 shares of the medical equipment provider’s stock worth $1,783,000 after buying an additional 900 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. acquired a new position in Lantheus during the second quarter worth $2,830,000. Institutional investors and hedge funds own 91.50% of the company’s stock.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Recommended Story: Fundamental Analysis and Individual Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.